The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

References

• Dirkx AEM, Egbrink MGA, Castermans K, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006;20(6):621–630. doi: 10.1096/fj.05-4493com
   PubMed Web of Science ®Google Scholar
• Yasuda S, Sho M, Yamato I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol. 2013;172(3):500–506. doi: 10.1111/cei.12069
   PubMed Web of Science ®Google Scholar
• Przybylski DJ, Bergsbaken JJ, Piccolo JK. Unleashing the power of immunotherapy and targeted therapy combinations: advancing cancer care or discovering unknown toxicities? J Oncol Pharm Pract. 2021;27(4):930–938. doi: 10.1177/1078155220984235
   PubMed Web of Science ®Google Scholar
• Lombardi P, Filetti M, Falcone R, et al. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and a network meta-analysis. Cancer Treat Rev. 2022;106:102377. doi: 10.1016/j.ctrv.2022.102377
   PubMed Web of Science ®Google Scholar
• Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther. 2018;11:6227–6237. doi: 10.2147/OTT.S170138
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–2019. doi: 10.1016/S0140-6736(07)61865-0
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–5212. doi: 10.1200/JCO.2007.15.6331
   PubMed Web of Science ®Google Scholar
• Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol. 2011;29(25):3450–3456. doi: 10.1200/JCO.2010.34.4309
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Ciccarese C, Fornarini G, et al. Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. Br J Clin Pharmacol. 2019;85(6):1283–1289. doi: 10.1111/bcp.13895
   PubMed Web of Science ®Google Scholar
• Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–e458. doi: 10.1016/S1470-2045(18)30457-1
   PubMed Web of Science ®Google Scholar
• Salem J, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–1589. doi: 10.1016/S1470-2045(18)30608-9
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535. doi: 10.1136/bmj.b2535
   PubMed Web of Science ®Google Scholar
• Morris JA, Gardner MJ. Statistics in medicine: calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988;296(6632):1313–1316. doi: 10.1136/bmj.296.6632.1313
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Review manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014. http://ims.cochrane.org/revman/download
   Google Scholar
• Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–1573. doi: 10.1016/S1470-2045(20)30436-8
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. CLEAR trial investigators. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi: 10.1056/NEJMoa2035716
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. CheckMate 9ER investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi: 10.1056/NEJMoa2026982
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi: 10.1056/NEJMoa1816047
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–1844. doi: 10.1016/S0140-6736(20)30934-X
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herráez A, et al. Study 309–KEYNOTE-775 investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi: 10.1056/NEJMoa2108330
   PubMed Web of Science ®Google Scholar
• Kelley Rk T, Yau T, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma: Results from the randomized phase III COSMIC-312 trial. 2021 ESMO virtual plenary. Abstract VP10- 2021. cited 2021 Nov 20.
   Google Scholar
• Yarchoan M, Cope L, Ruggieri AN, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021;131(24):e152670. doi: 10.1172/JCI152670
   PubMed Web of Science ®Google Scholar
• Loriot Y, Grivas P, de Wit R, et al. First-line pembrolizumab with or without lenvatinib in patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind study. J Clin Oncol. 2022;40(suppl 6):432. doi: 10.1200/JCO.2022.40.6_suppl.432
   Web of Science ®Google Scholar
• Eng C, Kim TW, Bendell J, et al. For the IMblaze370 investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849–861. doi: 10.1016/S1470-2045(19)30027-0
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Longo DL. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–1467. doi: 10.1056/NEJMra1100265
   PubMed Web of Science ®Google Scholar
• Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409–425. doi: 10.1016/j.jash.2018.03.008
   PubMed Web of Science ®Google Scholar
• Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–868. doi: 10.1093/cvr/cvz026
   PubMed Web of Science ®Google Scholar
• Wang DY, Okoye GD, Neilan TG, et al. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19(3):21. doi: 10.1007/s11886-017-0835-0
   PubMed Web of Science ®Google Scholar
• Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med. 2013;23(4):104–113. doi: 10.1016/j.tcm.2012.09.008
   PubMed Web of Science ®Google Scholar
• Lankhorst S, Saleh L, Danser AJ, et al. Etiology of angiogenesis inhibition-related hypertension. Curr Opin Pharmacol. 2015;21:7–13. doi: 10.1016/j.coph.2014.11.010
   PubMed Web of Science ®Google Scholar
• Dalbeni A, Ciccarese C, Bevilacqua M, et al. Effects of antiangiogenetic drugs on microcirculation and macrocirculation in patients with advanced-stage renal cancer. Cancers (Basel). 2018;11(1):30. doi: 10.3390/cancers11010030
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–344. doi: 10.1038/nrc2106
   PubMed Web of Science ®Google Scholar
• May D, Gilon D, Djonov V, et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci. 2008;105:282–287.
   PubMed Web of Science ®Google Scholar
• Izumiya Y, Shiojima I, Sato K, et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47(5):887–893. doi: 10.1161/01.HYP.0000215207.54689.31
   PubMed Web of Science ®Google Scholar
• Iijima Y, Laser M, Shiraishi H, et al. C-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem. 2002;277(25):23065–23075. doi: 10.1074/jbc.M200328200
   PubMed Web of Science ®Google Scholar
• Sheng Z, Knowlton K, Chen J, et al. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem. 1997;272(9):5783–5791. doi: 10.1074/jbc.272.9.5783
   PubMed Web of Science ®Google Scholar
• Ramirez MT, Sah VP, Zhao XL, et al. The MEKK-JNK pathway is stimulated by α1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem. 1997;272(22):14057–14061. doi: 10.1074/jbc.272.22.14057
   PubMed Web of Science ®Google Scholar
• Lorenz K, Schmitt JP, Schmitteckert EM, et al. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med. 2009;15(1):75–83. doi: 10.1038/nm.1893
   PubMed Web of Science ®Google Scholar
• Guo CW, Alexander M, Dib Y, et al. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer. 2020;124:15–24. doi: 10.1016/j.ejca.2019.09.009
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarization (QT interval). Drug Saf. 2013;36(5):295–316. doi: 10.1007/s40264-013-0047-5
   PubMed Web of Science ®Google Scholar
• Naqash AR, Moey M, Tan XWC, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the national cancer institute—cancer therapy evaluation program. J Clin Oncol. 2022;40(29):3439–3452. doi: 10.1200/JCO.22.00369
   PubMed Web of Science ®Google Scholar
• Laenens D, Yu Y, Santes B, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40(29):3430–3438. doi: 10.1200/JCO.21.01808.
   PubMed Web of Science ®Google Scholar
• Lichtman AH. The heart of the matter: protection of the myocardium from T cells. J Autoimmun. 2013;45:90–96. doi: 10.1016/j.jaut.2013.05.004
   PubMed Web of Science ®Google Scholar
• Tarrio ML, Grabie N, Bu DX, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188(10):4876–4884. doi: 10.4049/jimmunol.1200389
   PubMed Web of Science ®Google Scholar
• Groschel C, Sasse A, Rohrborn C, et al. T helper cells with specificity for an antigen in cardiomyocytes promote pressure overload-induced progression from hypertrophy to heart failure. Sci Rep. 2017;7(1):15998. doi: 10.1038/s41598-017-16147-1
   PubMedGoogle Scholar
• Lutgens E, Seijkens TTP. Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease. J Immunother Cancer. 2020;8(1):e000300. doi: 10.1136/jitc-2019-000300
   PubMed Web of Science ®Google Scholar
• Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–1764. doi: 10.1016/j.jacc.2018.02.037
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6
   PubMed Web of Science ®Google Scholar
• Rini BI, Moslehi JJ, Bonaca M, et al. Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial. J Clin Oncol. 2022;40(17):1929–1938. doi: 10.1200/JCO.21.01806
   PubMed Web of Science ®Google Scholar
• Cautela J, Zeriouh S, Gaubert M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer. 2020;8(2):e001887. doi: 10.1136/jitc-2020-001887
   PubMed Web of Science ®Google Scholar